Synthesis and in vitro anti-proliferative activity of some novel isatins conjugated with quinazoline/phthalazine hydrazines against triple-negative breast cancer MDA …
Abstract Treatment of patients with triple-negative breast cancer (TNBC) is challenging due
to the absence of well-defined molecular targets and the heterogeneity of such disease. In …
to the absence of well-defined molecular targets and the heterogeneity of such disease. In …
[PDF][PDF] Synthesis and in vitro anti-proliferative activity of some novel isatins conjugated with quinazoline/phthalazine hydrazines against triple-negative breast cancer …
WM Eldehna, H Almahli, GH Al-Ansary… - JOURNAL OF …, 2017 - researchgate.net
Treatment of patients with triple-negative breast cancer (TNBC) is challenging due to the
absence of well-defined molecular targets and the heterogeneity of such disease. In our …
absence of well-defined molecular targets and the heterogeneity of such disease. In our …
Synthesis and in vitro anti-proliferative activity of some novel isatins conjugated with quinazoline/phthalazine hydrazines against triple-negative breast cancer MDA …
WM Eldehna, H Almahli, GH Al-Ansary… - Journal of Enzyme …, 2017 - search.proquest.com
Abstract Treatment of patients with triple-negative breast cancer (TNBC) is challenging due
to the absence of well-defined molecular targets and the heterogeneity of such disease. In …
to the absence of well-defined molecular targets and the heterogeneity of such disease. In …
Synthesis and in vitro anti-proliferative activity of some novel isatins conjugated with quinazoline/phthalazine hydrazines against triple-negative breast cancer MDA …
WM Eldehna, H Almahli… - Journal of enzyme …, 2017 - pubmed.ncbi.nlm.nih.gov
Treatment of patients with triple-negative breast cancer (TNBC) is challenging due to the
absence of well-defined molecular targets and the heterogeneity of such disease. In our …
absence of well-defined molecular targets and the heterogeneity of such disease. In our …
Synthesis and in vitro anti-proliferative activity of some novel isatins conjugated with quinazoline/phthalazine hydrazines against triple-negative breast cancer MDA …
WM Eldehna, H Almahli, GH Al-Ansary… - Journal of Enzyme …, 2017 - europepmc.org
Abstract Treatment of patients with triple-negative breast cancer (TNBC) is challenging due
to the absence of well-defined molecular targets and the heterogeneity of such disease. In …
to the absence of well-defined molecular targets and the heterogeneity of such disease. In …
[HTML][HTML] Synthesis and in vitro anti-proliferative activity of some novel isatins conjugated with quinazoline/phthalazine hydrazines against triple-negative breast cancer …
WM Eldehna, H Almahli, GH Al-Ansary… - Journal of Enzyme …, 2017 - ncbi.nlm.nih.gov
Abstract Treatment of patients with triple-negative breast cancer (TNBC) is challenging due
to the absence of well-defined molecular targets and the heterogeneity of such disease. In …
to the absence of well-defined molecular targets and the heterogeneity of such disease. In …
[引用][C] Synthesis and in vitro anti-proliferative activity of some novel isatins conjugated with quinazoline/phthalazine hydrazines against triple-negative breast cancer …
WM Eldehna, H Almahli, GH Al-Ansary… - Journal of Enzyme …, 2017 - cir.nii.ac.jp
Synthesis and <i>in vitro</i> anti-proliferative activity of some novel isatins conjugated with
quinazoline/phthalazine hydrazines against triple-negative breast cancer MDA-MB-231 cells …
quinazoline/phthalazine hydrazines against triple-negative breast cancer MDA-MB-231 cells …
Synthesis and in vitro anti-proliferative activity of some novel isatins conjugated with quinazoline/phthalazine hydrazines against triple-negative breast cancer MDA …
WM Eldehna, H Almahli, GH Al-Ansary… - Journal of Enzyme …, 2017 - europepmc.org
Abstract Treatment of patients with triple-negative breast cancer (TNBC) is challenging due
to the absence of well-defined molecular targets and the heterogeneity of such disease. In …
to the absence of well-defined molecular targets and the heterogeneity of such disease. In …
[PDF][PDF] Synthesis and in vitro anti-proliferative activity of some novel isatins conjugated with quinazoline/phthalazine hydrazines against triple-negative breast cancer …
OE Ismael, A Al-Dhfyan… - JOURNAL OF ENZYME …, 2017 - researchgate.net
Treatment of patients with triple-negative breast cancer (TNBC) is challenging due to the
absence of well-defined molecular targets and the heterogeneity of such disease. In our …
absence of well-defined molecular targets and the heterogeneity of such disease. In our …